Panacea Index Logo

Command Palette

Search for a command to run...

Depression in Pregnancy.

Revista Colombiana de psiquiatria (English ed.)
January 1, 2019
Jhon Freddy Martínez-Paredes et al. (2 authors)
Journal ArticleReviewHuman Study
Study Details

Study Goal

The researchers aimed to review depression in pregnancy, including its risk factors, clinical characteristics, complications, and treatment options, with mindfulness mentioned as a non-pharmacological intervention.

Results Summary

The study concluded that mindfulness, alongside psychotherapy and aerobic exercise, is recommended as a non-pharmacological treatment for depression in pregnancy, though specific efficacy data for mindfulness alone were not detailed.

Population

Pregnant women with depression, particularly in South America.

Effective Dosage

Not available

Duration

Not specified

Interactions

None mentioned

Extracted Claims (5)
InterventionDirectionEndpointPopulationDosageImpactClaim #
early diagnosis
decrease
risk behaviour, foetal neurodevelopmental disorders and obstetric outcomes
pregnant women with depression
-
favours a reduction in
#1
selective serotonin reuptake inhibitor antidepressants, particularly fluoxetine
neutral
depression in pregnancy
pregnant women
-
is recommended
#2
fluoxetine
no change
teratogenicity
-
-
has not been associated with
#3
non-pharmacological treatment such as psychotherapy, mindfulness and aerobic exercise
neutral
depression in pregnancy
pregnant women
-
is recommended in addition to
#4
educating healthcare professionals
neutral
depression in pregnancy
pregnant women
-
will facilitate the correct diagnosis and treatment of
#5
Abstract

INTRODUCTION: Depression is the most common psychiatric morbidity in pregnancy, affecting more than 13% of pregnant women. Its diagnosis is based on the criteria established by the DSM-5 and the application of validated scales such as the Edinburgh Postnatal Depression Scale. However, there are still errors and shortcomings among healthcare professionals in the recognition, diagnosis and treatment of depression during pregnancy, with the resulting consequences and repercussions on the gestation itself or the foetus. OBJECTIVE: To present a review of depression in pregnancy, its risk factors, clinical characteristics, complications and treatment. METHODS: The PubMed and LILACS databases were used to search for manuscripts. Of the 223 articles found, 55 fulfilled the inclusion criteria. RESULTS: The prevalence of depression in pregnancy in South America is approximately 29% and the most significant risk factors are sexual abuse, pregnancy at an early age and intrafamily violence. Therefore, early diagnosis favours a reduction in risk behaviour, foetal neurodevelopmental disorders and obstetric outcomes. CONCLUSIONS: Depression in pregnancy is common condition but is underreported as its symptoms are often attributed to the pregnancy itself. The use of selective serotonin reuptake inhibitor antidepressants, particularly fluoxetine, which has not been associated with teratogenicity, is recommended, in addition to the implementation of non-pharmacological treatment such as psychotherapy, mindfulness and aerobic exercise. Educating healthcare professionals will facilitate the correct diagnosis and treatment of this condition.

Medical Subject Headings (MeSH)
DepressionFemaleFluoxetineHumansPregnancyPregnancy ComplicationsPrevalencePsychiatric Status Rating ScalesRisk FactorsSelective Serotonin Reuptake Inhibitors
Study Links
Quality Scores
SafetyNot Assessed
Efficacy70/10
Quality75/10
Citation Metrics
Total Citations21
Citations/Year3.5
Relative Citation Ratio2.04
NIH Percentile75.1%
Research Impact Scores
APT Score0.75
Weight Score2.19
Normalized Score0.63
Related Supplements